A first-in-class multimodal organomercury compound demonstrates preferential blast reduction with improved hematopoietic and immune health in ALL
The study demonstrates that a novel organomercury curcumin derivative, -Mercurin, outperforms the clinical standard cytarabine in an ALL rat model by effectively reducing leukemic blasts while simultaneously restoring hematopoietic and immune health with a superior safety profile and favorable pharmacokinetics.